U.S. Markets open in 2 hrs 42 mins

NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey--(BUSINESS WIRE)--

Novocure (NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma (GBM) in its globally recognized Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers.

NCCN panel members designated alternating electric field therapy, or Optune, as a Category 1 treatment recommendation for patients with newly diagnosed GBM in conjunction with temozolomide after maximal safe resection and completion of radiation therapy in patients with newly diagnosed GBM.

The updated recommendation follows the publication of Novocure’s EF-14 phase 3 pivotal trial five-year survival results in the Journal of the American Medical Association (JAMA) in December 2017. The EF-14 five-year survival results demonstrated Optune plus temozolomide significantly improved survival outcomes in patients with newly diagnosed GBM compared to temozolomide alone. A category 1 recommendation indicates, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

“Many physicians look to the NCCN Guidelines as the standard resource when determining the best course of treatment for patients,” said Asaf Danziger, Novocure’s Chief Executive Officer. “The introduction of Optune with temozolomide gives newly diagnosed GBM patients the potential for long-term survival. We believe the updated NCCN guidelines will increase physician awareness, particularly in the radiation oncology and medical oncology communities, helping us to reach patients earlier in the course of this aggressive disease.”

Optune has robust real-world evidence in GBM with more than 1,800 patients on therapy as of December 31, 2017 and more than 7,000 GBM patients treated to date. Physicians at more than 700 cancer centers in the U.S. – and at more than 1,100 medical institutions globally – have been certified to prescribe Optune to newly diagnosed and recurrent GBM patients.

About National Comprehensive Cancer Network

NCCN is a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians and other health care decision-makers.

About Novocure

Novocure is a global oncology company developing a proprietary platform technology called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Approved Indications

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005857/en/

  • What happens if you win Mega Millions' $970M jackpot?
    News
    Associated Press

    What happens if you win Mega Millions' $970M jackpot?

    Despite the terrible odds — one in 302.5 million for those keeping score at home — someone will eventually match all six numbers and win the Mega Millions jackpot, which now stands at $970 million. Here are some answers for someone holding that prized lottery ticket for what would be the second-largest lottery jackpot in U.S. history. Lottery officials recommend winners take a deep breath, put their winning ticket in a safe spot and consult with a reputable financial planner before popping over to the lottery headquarters.

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight
    Politics
    Time

    Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight

    To understand what it means to be famous like Stormy Daniels, for the reasons she is famous, spend time with her in a public space. On Oct. 15, a California judge threw out the defamation case she filed against Donald Trump. Over the past year, Daniels, 39, has become the Zelig of White House scandals.

  • Tesla Starts Taking Orders for Shorter-Range $45,000 Model 3
    Business
    Bloomberg

    Tesla Starts Taking Orders for Shorter-Range $45,000 Model 3

    The electric-car maker has started taking orders for a mid-range battery Model 3 that goes about 260 miles between charges for $45,000. Offering cheaper versions of the vehicle raised a “big and unanswered question” of Tesla maintaining profit targets for the car, he said. While Tesla is making the Model 3 more accessible to some buyers, the starting price for sedans with the long-range battery is rising to $54,000.

  • 7 Stocks Warren Buffett Can’t Stop Buying
    Finance
    InvestorPlace

    7 Stocks Warren Buffett Can’t Stop Buying

    Sometimes identifying the best stocks to buy can be difficult, but you could do a lot worse than checking out the stocks selected by one of the world’s savviest hedge fund managers — Warren Buffett. Buffett’s stock picks are a popular source for investors, and for good reason. The billionaire Buffett is many things: He’s among the world’s most successful fund managers, a legendary philanthropist and owns more than 60 companies.

  • Goldman Sachs Adds Nvidia To 'Conviction Buy' List
    Business
    Yahoo Finance Video

    Goldman Sachs Adds Nvidia To 'Conviction Buy' List

    Goldman Sachs analyst Toshiya Hari reiterated his 'Buy' rating for Nvidia and added the chip-maker to Goldman’s 'Conviction Buy' list.

  • Business
    Reuters

    Micron to buy Intel's stake in joint venture IM Flash Technologies

    The deal terms include payment of about $1.5 billion in cash, as well as taking over Intel's debt to the venture, which was about $1 billion as of Aug. 30, Micron said. Intel and Micron initially contributed about $1.2 billion each to set up IM Flash Technologies in 2006. IM Flash (Intel-Micron Flash) makes 3D XPoint used in data centres and high-end computers and the joint venture is already consolidated in Micron's reported financial statements.

  • Home Depot vs. Lowe’s: Both Stocks Are Slumping, So Which One Should You Buy?
    Finance
    GoBankingRates

    Home Depot vs. Lowe’s: Both Stocks Are Slumping, So Which One Should You Buy?

    An analyst downgrade based on housing market outlooks has sent stocks from Lowe’s and Home Depot down over the last two days. Both Home Depot and Lowe’s are in downtrends dating back to September. On Wednesday, shares in Lowe’s and The Home Depot were slumping after disappointing housing market data led a key analyst to downgrade his ratings and slash price targets, and both stocks continued the slump into a second day on Thursday.

  • Ford Motor Company Earnings: What to Watch For
    Business
    Motley Fool

    Ford Motor Company Earnings: What to Watch For

    Ford Motor Company (NYSE: F) will report its third-quarter earnings results after the markets close on Oct. 24. Wall Street analysts polled by Thomson Reuters expect Ford to report earnings of $0.30 per share, on average, down from $0.43 in the third quarter of 2017. Ford's F-Series pickups continue to sell well and generate good profits, thanks to high-margin versions like this F-150 Limited.

  • Aurora Cannabis stock leads sector higher after news it will start trading on NYSE next week
    News
    MarketWatch

    Aurora Cannabis stock leads sector higher after news it will start trading on NYSE next week

    Canadian marijuana company Aurora Cannabis Inc.’s shares rose about 4% Thursday after it said shares have been approved for trading on the New York Stock Exchange starting October 23. The stock (CA:ACB)(CA:ACB) which is currently trading on the over-the-counter market, will trade under the ticker symbol “ACB”. The shares are also traded on the Toronto Stock Exchange.

  • Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment
    Finance
    American City Business Journals

    Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment

    New details have emerged about the killing of journalist Jamal Khashoggi by Saudi agents — involving his beheading and dismemberment upon entering the Saudi consulate in Istanbul, Turkey — thanks to audio files described by Turkish officials. As evidence mounts of the Washington Post columnist’s gruesome death tied to Saudi Arabia, Bay Area tech companies, which have gobbled up billions in funding from the kingdom in recent years, could see that money river dry up as Saudi investment becomes increasingly toxic. President Donald Trump has criticized those rushing to condemn the nation, telling the Associated Press: "You know, you’re guilty until proven innocent." Yet even still, Japanese investor Softbank isn’t stomaching the brutal killing tied to its major investment fund so easily.

  • Finance
    CNBC

    China's stock market is getting pummeled and history shows that is bad news for US markets

    U.S. stocks are lower about 70 percent of the time in periods when there are big drops of 10 percent or more in Shanghai stocks, according to analytics firm Kensho. The main U.S. indexes lose about 5 percent when Shanghai stocks fall 10 percent or more in a 30-day period. Big blue chips, like Goldman and Caterpillar are among the losers, but copper and oil also fall hard when Shanghai sees a big decline.

  • Employee Accused of Urinating on Production Line at Food Processing Facility
    Business
    WTKR - Norfolk

    Employee Accused of Urinating on Production Line at Food Processing Facility

    Smithfield Foods, Inc. said in a statement Tuesday that it disposed of more than 50,000 pounds of product after reports of an employee urinating at his station at the company’s processing facility in Virginia.

  • Nokia in Q3 2018: Why Analysts Are Estimating Lower
    Finance
    Market Realist

    Nokia in Q3 2018: Why Analysts Are Estimating Lower

    Nokia (NOK) is expected to announce its third-quarter earnings on October 25. Analysts expect revenue of $6.4 billion compared to $6.46 billion in Q3 2017, indicating a year-over-year decline of 1%. Revenues for Ericsson (ERIC) and Juniper Networks (JNPR) are expected to fall 4.2% and 6.5%, respectively, in their current quarters.

  • Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For
    Business
    Zacks

    Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For

    Advanced Micro Devices (AMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 24, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Business
    TheStreet.com

    Trading Nvidia After Goldman Sachs Upgrades to 'Conviction Buy'

    shares were doing well, up more than 1% after Goldman Sachs analysts placed the stock on its conviction buy list. It's been a bumpy ride for Nvidia this month, as the waves of selling in the broader market have taken their toll. In any regard, Goldman took Nvidia up to conviction buy with a $305 price target.

  • Finance
    IPO-Edge.com

    Why Warren Buffett and a Wal-Mart Heir Want a Slice of This Brazilian Payments IPO

    Warren Buffett and Wal-Mart heir Rob Walton are buying tickets to Brazil. Should investors join them for the ride? Brazilian digital-payments company StoneCo (ticker: STNE) plans to sell up to $1.1 billion in an offering of new and existing shares, valuing the company at $6.2 billion if they price at the top of the indicative range.

  • The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse
    Business
    Business Insider

    The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse

    Inversion is a mental model that involves flipping your outlook to prevent the opposite of what you want to happen from happening. Warren Buffett and his business partner Charlie Munger employed inversion as a business strategy to build Berkshire Hathaway into a powerhouse. In a recent podcast with Brandon of the Mad Fientist, who retired early at 34, productivity expert James Clear said the same strategy Buffett used can help set someone on the path for early retirement.

  • Finance
    Investopedia

    Berkshire Is Undervalued, Says JPMorgan

    Berkshire Hathaway Inc.'s ( BRK.B) Class B shares are cheap if you apply the same metrics that its CEO Warren Buffett does to value companies, according to JPMorgan. In a research note, reported on by CNBC, analyst Sarah DeWitt said Berkshire, a company that investors have historically struggled to value properly because of its many moving parts, suddenly appears to be attractively priced when factoring in all the profits made by the stocks held in its $200 billion equity portfolio into its earnings. “Look-through earnings” take into account current period earnings that show up in financial statements, together with other sources of earnings expected in the long run. This method is used by Buffett as a way to appreciate that companies sometimes retain earnings after paying dividends and later invest them at a higher rate of return.

  • Berkshire Hathaway Inc. (BRK.B) Stock Moves -0.55%: What You Should Know
    Business
    Zacks

    Berkshire Hathaway Inc. (BRK.B) Stock Moves -0.55%: What You Should Know

    Heading into today, shares of the company had lost 4.72% over the past month, lagging the Finance sector's loss of 3.07% and the S&P 500's loss of 2.61% in that time. For the full year, our Zacks Consensus Estimates are projecting earnings of $9.90 per share and revenue of $248.35 billion, which would represent changes of +68.94% and +2.56%, respectively, from the prior year. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

  • Business
    CNBC

    Want to work for Jack Ma? These are the traits he looks for in a candidate

    For Jack Ma , the man behind Chinese tech giant Alibaba BABA , that's a process that took him some time to master. Ma, speaking in the Indonesia resort island of Bali last week, recalled a hiring mistake he made in the early days of Alibaba. As it turned out, that plan was designed to cost $12 million — way over the spending budget that the company could afford back then, Ma explained.

  • Canada Has Legalized Marijuana. Here's What That Means For American Travelers
    Business
    Time

    Canada Has Legalized Marijuana. Here's What That Means For American Travelers

    Recreational marijuana is now legal across Canada, giving millions of people the right to buy, carry and grow cannabis. “Regardless of Canada’s legalization of marijuana today, nothing will be changing on the U.S. side or with CBP policies and procedures at the border,” Malin said via email. U.S. residents are free to consume cannabis in Canada, but they should leave it behind when returning home, says Erik Altieri, the executive director of the National Organization for the Reform of Marijuana laws (NORML).

  • Boeing (BA) Dips More Than Broader Markets: What You Should Know
    Finance
    Zacks

    Boeing (BA) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Boeing (BA) closed at $359.50, marking a -1.64% move from the previous day. This change lagged the S&P 500's 1.44% loss on the day. Meanwhile, the Dow lost 1.27%, and the Nasdaq, a tech-heavy index, lost 2.06%.Coming into

  • Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot
    News
    MarketWatch

    Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot

    Aurora Cannabis Inc. is a major pot producer, but if its bets on other cannabis companies continue to pay off, it may be able to stop actually growing weed on its own. Aurora (ACBFF)(CA:ACB) said recently its investments were worth more than C$700 million ($540 million) as of Sept. 21, bolstered in part by demand for pot stocks ahead of full legalization of marijuana in Canada on Wednesday. As the entire sector has benefited, so has Aurora’s portfolio, boosting the company’s fiscal fourth-quarter profit to C$79.9 million, after a loss of $20.8 million the year earlier.

  • General Motors Earnings: What to Watch
    Business
    Motley Fool

    General Motors Earnings: What to Watch

    General Motors (NYSE: GM) will report its third-quarter earnings results before the U.S. markets open on Wednesday, Oct. 31. Wall Street thinks that GM's revenue may improve year over year, but it may fall a bit short of that earnings number this time around. GM has just begun rolling out all-new versions of its big-selling Chevrolet Silverado and GMC Sierra pickups.